Literature DB >> 11749047

Effect of maternal blood phenylalanine level on mouse maternal phenylketonuria offspring.

S Cho1, J D McDonald.   

Abstract

The genetic mouse model BTBR-Pah(enu2) was used to more thoroughly investigate the pathogenesis of maternal phenylketonuria (MPKU). More specifically, it was used to examine the effect of maternal blood phenylalanine (PHE) level on the pregnancy outcome of MPKU offspring as determined by certain key measures of development at birth (i.e., head circumference, weight, and crown-rump length of offspring). In this study, we clearly observed that elevated maternal blood PHE levels, whether they were caused by the maternal diet or the maternal genotype, were responsible for fetal abnormalities. As in human MPKU, significant reductions (P < 0.0001) in birth weight, crown-rump length, and head circumference were seen in offspring gestated under the condition of high maternal blood PHE levels. These findings strongly suggest that there are sufficient similarities between human MPKU and MPKU in this mouse model to establish it as a very promising model for future studies designed to characterize human MPKU more thoroughly. Copyright 2001 Elsevier Science.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11749047     DOI: 10.1006/mgme.2001.3255

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  7 in total

Review 1.  State-of-the-Art 2019 on Gene Therapy for Phenylketonuria.

Authors:  Hiu Man Grisch-Chan; Gerald Schwank; Cary O Harding; Beat Thöny
Journal:  Hum Gene Ther       Date:  2019-09-09       Impact factor: 5.695

2.  Developmental timing of exposure to elevated levels of phenylalanine is associated with ADHD symptom expression.

Authors:  Kevin M Antshel; Susan E Waisbren
Journal:  J Abnorm Child Psychol       Date:  2003-12

Review 3.  State-of-the-art 2003 on PKU gene therapy.

Authors:  Zhaobing Ding; Cary O Harding; Beat Thöny
Journal:  Mol Genet Metab       Date:  2004-01       Impact factor: 4.797

4.  Cardiac teratogenicity in mouse maternal phenylketonuria: defining phenotype parameters and genetic background influences.

Authors:  Nikki J Seagraves; Kim L McBride
Journal:  Mol Genet Metab       Date:  2012-08-08       Impact factor: 4.797

5.  Effect of developmental NMDAR antagonism with CGP 39551 on aspartame-induced hypothalamic and adrenal gene expression.

Authors:  Kate S Collison; Angela Inglis; Sherin Shibin; Soad Saleh; Bernard Andres; Rosario Ubungen; Jennifer Thiam; Princess Mata; Futwan A Al-Mohanna
Journal:  PLoS One       Date:  2018-03-21       Impact factor: 3.240

Review 6.  Engineering Organoids for in vitro Modeling of Phenylketonuria.

Authors:  Alice C Borges; Kerensa Broersen; Paula Leandro; Tiago G Fernandes
Journal:  Front Mol Neurosci       Date:  2022-01-10       Impact factor: 5.639

7.  Protective effect of recombinant adeno-associated virus 2/8-mediated gene therapy from the maternal hyperphenylalaninemia in offsprings of a mouse model of phenylketonuria.

Authors:  Sung-Chul Jung; Joo-Won Park; Hyun-Jeong Oh; Jin-Ok Choi; Kyung-In Seo; Eun-Sook Park; Hae-Young Park
Journal:  J Korean Med Sci       Date:  2008-10       Impact factor: 2.153

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.